Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies,
such as rituximab, can block cancer growth in different ways. Some find cancer cells and help
kill them or carry cancer-killing substances to them. Others interfere with the ability of
cancer cells to grow and spread. Giving combination chemotherapy together with rituximab may
kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving combination chemotherapy together
with rituximab works in treating patients with newly diagnosed AIDS-related B-cell
non-Hodgkin's lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
AIDS Malignancy Consortium
Collaborators:
National Cancer Institute (NCI) The Emmes Company, LLC The EMMES Corporation